Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results, Misses Expectations By $0.14 EPS

Structure Therapeutics (NASDAQ:GPCR) announced its earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14), Zacks reports.

Structure Therapeutics Stock Down 2.7%

Shares of GPCR stock opened at $64.75 on Friday. The business has a fifty day simple moving average of $75.45 and a 200 day simple moving average of $46.22. The company has a market cap of $4.57 billion, a P/E ratio of -53.07 and a beta of -2.06. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $94.90.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in Structure Therapeutics by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Structure Therapeutics by 14.4% during the fourth quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock worth $354,006,000 after buying an additional 641,322 shares in the last quarter. Morgan Stanley increased its holdings in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Structure Therapeutics by 477.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after acquiring an additional 1,381,745 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Structure Therapeutics by 7.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock valued at $32,939,000 after acquiring an additional 106,389 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

GPCR has been the subject of a number of recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. Guggenheim boosted their price target on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. HC Wainwright raised their price objective on Structure Therapeutics from $60.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Citizens Jmp lifted their price objective on Structure Therapeutics from $87.00 to $120.00 and gave the company a “market outperform” rating in a report on Friday, December 12th. Finally, Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $106.20.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.